A functional polymorphism in the HMGCR promoter affects transcriptional activity but not the risk for Alzheimer disease in Swedish populations.

Keller L, Murphy C, Wang HX, Fratiglioni L, Olin M, Gafvels M, Björkhem I, Graff C, Meaney S

Brain Res. 1344 (-) 185-191 [2010-07-16; online 2010-05-11]

Variations in genes associated with cholesterol homeostasis have been reported to modify the risk of developing Alzheimer disease (AD). To date there have been few investigations into variations in genes directly involved in cholesterol biosynthesis and AD. We investigated the influence of the -911C>A polymorphism (rs3761740) in the hydroxy-methyl-glutaryl CoA reductase (HMGCR) gene promoter on basal and regulated transcription, plasma cholesterol levels and the association with AD. Under in vitro conditions the A allele was found to be significantly more responsive to SREBP-2 mediated regulation than the C allele. In an age and sex matched case-control study, the genotype distribution and allele frequency of this polymorphism were not associated with AD (OR=1.03; 95% CI=0.72-1.48). However, we did find evidence supporting an interaction between the HMGCR A allele, the APOE E4 allele and an altered risk of AD (OR=2.41; 95% CI=0.93-6.22).

Mutation Analysis Facility (MAF)

PubMed 20450896

DOI 10.1016/j.brainres.2010.04.073

Crossref 10.1016/j.brainres.2010.04.073

pii: S0006-8993(10)01009-7